Search 

SomaServe's PolyNaut platform addresses the ‘delivery problem’. Reaching the site of action is one of the most pressing challenges in the advancement of gene therapy and the development of protein therapeutics for intracellular targets.

Using polyNaut technology we are uniquely able to address the shortcomings of viral or lipid-based delivery technologies by encapsulating a range of therapeutic modalities into polymer nanovesicles that can penetrate the blood brain barrier effectively and selectively target different tissues and cell types. 

Through partnerships we are deploying PolyNaut to develop a next generation of gene therapies and intracellular proteins in oncology, immunology and CNS disorders.

Therakind, a private European pharmaceutical company, is focused on creating and developing safe, effective, authorised paediatric and speciality niche medicines. Our primary objective is to increase the availability of authorised paediatric and niche medicines and to ensure that the medication used today is both safe and effective.

Therakind's team has extensive experience in the paediatric pharmaceutical sector, we have the expertise to design clinical programmes and regulatory strategy to advance medicines from concept through to regulatory approval.

Therakind was pivotal in the process of bringing Buccolam®, a treatment for prolonged acute convulsive seizures, to the EU market. This product has been sold to Viropharma Inc (now Shire Pharmaceuticals) and is marketed across Europe.

Therakind is a private European pharmaceutical company established in 2006.